Evidence map›Paper›PMID 42630141›Full record

ArticleFrontiers in ophthalmology2026

Display color gamut as a spectral risk factor for myopia: a unifying hypothesis linking chromatic emmetropization, cone circuitry dysfunction, and the spectral deficiency of digital screens.

Pierpaolo Emanuele Maimone

Abstract read
In one paragraph

Article in Frontiers in ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Pierpaolo Emanuele MaimoneOphthalmology and Vision Science, Studio Maimone, S. Teresa di Riva, Messina, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The global prevalence of myopia in children rose from 24% in 1990 to 36% in 2023, with projections exceeding 39% by 2050. While time spent outdoors is robustly protective against myopia, the specific spectral properties of light responsible for this protection remain insufficiently characterized. We propose that the spectral power distribution (SPD) of modern digital displays may represent a previously unrecognized environmental risk factor for myopia through the systematic elimination of two wavelength bands critical to emmetropization. All current display technologies emit no measurable light below approximately 420 nm, entirely excluding the violet band (360-400 nm) that activates OPN5/neuropsin (λmax ≈ 380 nm) in retinal ganglion cells. Additionally, the narrow-band RGB primary architecture of displays distorts the cyan-green region (490-560 nm), potentially perturbing the SWS/LWS opponent chromatic signal that the Gawne-Norton dual-detector model identifies as the primary longitudinal chromatic aberration (LCA)-based drive for emmetropization. These two mechanisms are consistent with the dose-response relationship between screen time and myopia risk documented in large-scale epidemiological studies. The hypothesis is grounded in five converging lines of evidence: (1) the OPN5/violet light pathway; (2) the LCA dual-detector emmetropization model; (3) genetic evidence from Blue Cone Monochromacy and Bornholm Eye Disease; (4) red-light therapy trials; and (5) subgroup analyses by display device type. We propose that display color gamut - and the spectral power distribution it determines - currently optimized exclusively for colorimetric fidelity, merits evaluation as a modifiable variable in the global myopia control agenda.

Indexed as

color gamutcone dysfunctiondigital displaysemmetropizationlongitudinal chromatic aberrationmyopianeuropsinOPN5

Identifiers

PMID42630141
PMCPMC13493264

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.